246 related articles for article (PubMed ID: 23675941)
1. Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease.
Reid TE; Kumar K; Wang XS
Curr Top Med Chem; 2013; 13(11):1353-62. PubMed ID: 23675941
[TBL] [Abstract][Full Text] [Related]
2. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
[TBL] [Abstract][Full Text] [Related]
3. Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors.
Kim SK; Li Y; Abrol R; Heo J; Goddard WA
J Chem Inf Model; 2011 Feb; 51(2):420-33. PubMed ID: 21299232
[TBL] [Abstract][Full Text] [Related]
4. Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy.
Cavero I; Guillon JM
J Pharmacol Toxicol Methods; 2014; 69(2):150-61. PubMed ID: 24361689
[TBL] [Abstract][Full Text] [Related]
5. A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.
Canal CE; Morgan D; Felsing D; Kondabolu K; Rowland NE; Robertson KL; Sakhuja R; Booth RG
J Pharmacol Exp Ther; 2014 May; 349(2):310-8. PubMed ID: 24563531
[TBL] [Abstract][Full Text] [Related]
6. Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs.
Hajjo R; Grulke CM; Golbraikh A; Setola V; Huang XP; Roth BL; Tropsha A
J Med Chem; 2010 Nov; 53(21):7573-86. PubMed ID: 20958049
[TBL] [Abstract][Full Text] [Related]
7. Identification of structural determinants of ligand selectivity in 5-HT₂ receptor subtypes on the basis of protein-ligand interactions.
Jang JW; Kim MS; Cho YS; Cho AE; Pae AN
J Mol Graph Model; 2012 Sep; 38():342-53. PubMed ID: 23085173
[TBL] [Abstract][Full Text] [Related]
8. (1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity.
Booth RG; Fang L; Huang Y; Wilczynski A; Sivendran S
Eur J Pharmacol; 2009 Aug; 615(1-3):1-9. PubMed ID: 19397907
[TBL] [Abstract][Full Text] [Related]
9. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist.
Dunlop J; Watts SW; Barrett JE; Coupet J; Harrison B; Mazandarani H; Nawoschik S; Pangalos MN; Ramamoorthy S; Schechter L; Smith D; Stack G; Zhang J; Zhang G; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2011 Jun; 337(3):673-80. PubMed ID: 21402690
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.
Fevig JM; Feng J; Rossi KA; Miller KJ; Wu G; Hung CP; Ung T; Malmstrom SE; Zhang G; Keim WJ; Cullen MJ; Rohrbach KW; Qu Q; Gan J; Pelleymounter MA; Robl JA
Bioorg Med Chem Lett; 2013 Jan; 23(1):330-5. PubMed ID: 23177783
[TBL] [Abstract][Full Text] [Related]
11. Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors.
Nelson DL; Lucaites VL; Wainscott DB; Glennon RA
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jan; 359(1):1-6. PubMed ID: 9933142
[TBL] [Abstract][Full Text] [Related]
12. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
Rickli A; Moning OD; Hoener MC; Liechti ME
Eur Neuropsychopharmacol; 2016 Aug; 26(8):1327-37. PubMed ID: 27216487
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
Knight AR; Misra A; Quirk K; Benwell K; Revell D; Kennett G; Bickerdike M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):114-23. PubMed ID: 15322733
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Concern of 5-HT2B Receptor and Recent Vistas in the Development of Its Antagonists.
Padhariya K; Bhandare R; Canney D; Velingkar V
Cardiovasc Hematol Disord Drug Targets; 2017; 17(2):86-104. PubMed ID: 28676029
[TBL] [Abstract][Full Text] [Related]
15. Serotonergic drugs and valvular heart disease.
Rothman RB; Baumann MH
Expert Opin Drug Saf; 2009 May; 8(3):317-29. PubMed ID: 19505264
[TBL] [Abstract][Full Text] [Related]
16. Selective 5-HT2C receptor agonists: Design and synthesis of pyridazine-fused azepines.
Green MP; McMurray G; Storer RI
Bioorg Med Chem Lett; 2016 Aug; 26(16):4117-21. PubMed ID: 27381086
[TBL] [Abstract][Full Text] [Related]
17. Emerging opportunities and concerns for drug discovery at serotonin 5-HT2B receptors.
Brea J; Castro-Palomino J; Yeste S; Cubero E; Párraga A; Domínguez E; Loza MI
Curr Top Med Chem; 2010; 10(5):493-503. PubMed ID: 20166944
[TBL] [Abstract][Full Text] [Related]
18. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
Cussac D; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Martel JC; Danty N; Rauly-Lestienne I
Eur J Pharmacol; 2008 Oct; 594(1-3):32-8. PubMed ID: 18703043
[TBL] [Abstract][Full Text] [Related]
19. A new class of 5-HT
Casey AB; Mukherjee M; McGlynn RP; Cui M; Kohut SJ; Booth RG
Br J Pharmacol; 2022 Jun; 179(11):2610-2630. PubMed ID: 34837227
[TBL] [Abstract][Full Text] [Related]
20. Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors.
Storer RI; Brennan PE; Brown AD; Bungay PJ; Conlon KM; Corbett MS; DePianta RP; Fish PV; Heifetz A; Ho DK; Jessiman AS; McMurray G; de Oliveira CA; Roberts LR; Root JA; Shanmugasundaram V; Shapiro MJ; Skerten M; Westbrook D; Wheeler S; Whitlock GA; Wright J
J Med Chem; 2014 Jun; 57(12):5258-69. PubMed ID: 24878222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
